RS62602B1 - Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc - Google Patents

Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc

Info

Publication number
RS62602B1
RS62602B1 RS20211445A RSP20211445A RS62602B1 RS 62602 B1 RS62602 B1 RS 62602B1 RS 20211445 A RS20211445 A RS 20211445A RS P20211445 A RSP20211445 A RS P20211445A RS 62602 B1 RS62602 B1 RS 62602B1
Authority
RS
Serbia
Prior art keywords
lung cancer
cancer including
against several
immunotherapy against
several tumors
Prior art date
Application number
RS20211445A
Other languages
English (en)
Inventor
Jens Fritsche
Harpreet Singh
Colette Song
Steffen Walter
Toni Weinschenk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en
Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority claimed from EP18201334.2A external-priority patent/EP3456339B1/en
Publication of RS62602B1 publication Critical patent/RS62602B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
RS20211445A 2013-08-05 2014-08-04 Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc RS62602B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361862213P 2013-08-05 2013-08-05
GBGB1313987.8A GB201313987D0 (en) 2013-08-05 2013-08-05 Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GBGB1403297.3A GB201403297D0 (en) 2014-02-25 2014-02-25 Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
EP18201334.2A EP3456339B1 (en) 2013-08-05 2014-08-04 Novel immunotherapy against several tumors, such as lung cancer including nsclc

Publications (1)

Publication Number Publication Date
RS62602B1 true RS62602B1 (sr) 2021-12-31

Family

ID=60955422

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211445A RS62602B1 (sr) 2013-08-05 2014-08-04 Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc

Country Status (19)

Country Link
US (17) US20170320913A1 (sr)
JP (4) JP6646017B2 (sr)
KR (2) KR20220045085A (sr)
CN (3) CN110041402B (sr)
AU (1) AU2022201167A1 (sr)
CL (6) CL2018002279A1 (sr)
CY (2) CY1122453T1 (sr)
ES (1) ES2900004T3 (sr)
HR (2) HRP20211852T1 (sr)
HU (1) HUE057334T2 (sr)
IL (5) IL300761A (sr)
LT (1) LT3456339T (sr)
MX (3) MX2021001914A (sr)
MY (1) MY191939A (sr)
PH (3) PH12018501901A1 (sr)
PL (1) PL3456339T3 (sr)
PT (1) PT3456339T (sr)
RS (1) RS62602B1 (sr)
SI (1) SI3456339T1 (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
RS62602B1 (sr) 2013-08-05 2021-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
CN112521484A (zh) * 2020-12-03 2021-03-19 佛山市第一人民医院（中山大学附属佛山医院） 结肠癌肿瘤特异tcr序列及其应用
CN112691195B (zh) * 2021-02-02 2023-03-14 黑龙江省科学院高技术研究院 Prpf8表达抑制剂在制备治疗肺癌的药物中的应用
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
AU2205499A (en) 1997-12-31 1999-07-19 Incyte Pharmaceuticals, Inc. Human regulatory proteins
US7094890B1 (en) 2000-03-10 2006-08-22 Novartis Ag Arthritis-associated protein
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
JP2005500059A (ja) 2001-08-13 2005-01-06 ダナ−ファーバー キャンサー インスティテュート インク． ペリオスチンに基づく診断アッセイ法
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
AU2003262789A1 (en) * 2002-08-20 2004-03-11 Aventis Pharma Sa Abca13 nucleic acids and proteins, and uses thereof
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
ATE511550T1 (de) * 2003-07-17 2011-06-15 Pacific Edge Biotechnology Ltd Marker zum nachweis von magenkrebs
EP1714157A2 (en) 2004-01-28 2006-10-25 Immatics Biotechnologies GmbH Method for identifying and quantifying of tumour-associated peptides
US20060019284A1 (en) 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
EP1642905B1 (en) 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
SI1760088T1 (sl) 2005-09-05 2008-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II
EA200801865A1 (ru) 2006-02-22 2009-02-27 Филоджен Спа Опухолевые маркеры сосудов
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
PL2338907T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
WO2009036246A2 (en) 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
US8134459B2 (en) 2007-10-19 2012-03-13 Smiths Medical Asd, Inc. Wireless telecommunications system adaptable for patient monitoring
US20100310640A1 (en) 2007-11-01 2010-12-09 Knutson Keith L Hla-dr binding peptides and their uses
EP2250287B1 (en) 2008-02-19 2013-09-18 MDxHealth SA Detection and prognosis of lung cancer
AU2009221915A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
CA2720563A1 (en) 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2010037124A1 (en) * 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
EP2172211B1 (en) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2010045388A2 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
GB2477705B (en) 2008-11-17 2014-04-23 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
CN101824400B (zh) * 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
US20110033516A1 (en) 2009-08-06 2011-02-10 Medical University Of South Carolina Methods and compositions for bone healing by periostin
US8281223B2 (en) 2009-08-07 2012-10-02 Via Technologies, Inc. Detection of fuse re-growth in a microprocessor
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9028810B2 (en) 2010-12-20 2015-05-12 Ajou University Industry—Academic Cooperations Foundatin Composition for inducing migration of neural stem cells containing periostin as effective ingredient
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
RS62602B1 (sr) * 2013-08-05 2021-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202111399YA (en) * 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Also Published As

Publication number Publication date
CL2021001794A1 (es) 2022-02-25
US10323065B1 (en) 2019-06-18
SI3456339T1 (sl) 2022-01-31
MX2021001914A (es) 2021-04-28
PH12020500433A1 (en) 2021-01-11
IL295031B2 (en) 2023-08-01
US20220064220A1 (en) 2022-03-03
US11939400B2 (en) 2024-03-26
US20200031870A1 (en) 2020-01-30
US20210253640A1 (en) 2021-08-19
US11866517B2 (en) 2024-01-09
CL2018002495A1 (es) 2018-10-26
PT3456339T (pt) 2021-12-09
US11814446B2 (en) 2023-11-14
US20190322703A1 (en) 2019-10-24
US10160786B1 (en) 2018-12-25
AU2022201167A1 (en) 2022-03-17
US20190177369A1 (en) 2019-06-13
US11859017B2 (en) 2024-01-02
CN110041402B (zh) 2024-04-16
JP2018038388A (ja) 2018-03-15
US20200031869A1 (en) 2020-01-30
IL295031B1 (en) 2023-04-01
US20200031868A1 (en) 2020-01-30
CY1124950T1 (el) 2023-01-05
JP2020010686A (ja) 2020-01-23
CN110041403B (zh) 2023-03-10
MY191939A (en) 2022-07-19
PL3456339T3 (pl) 2022-03-21
LT3456339T (lt) 2021-12-10
US10479818B2 (en) 2019-11-19
JP2022130482A (ja) 2022-09-06
US20220298207A1 (en) 2022-09-22
US20190002504A1 (en) 2019-01-03
US10316062B1 (en) 2019-06-11
US11939401B2 (en) 2024-03-26
JP7039044B2 (ja) 2022-03-22
ES2900004T3 (es) 2022-03-15
MX2018010565A (es) 2021-11-16
US20200017551A1 (en) 2020-01-16
US11161879B2 (en) 2021-11-02
HRP20211852T1 (hr) 2022-03-18
US10316063B1 (en) 2019-06-11
IL300761A (en) 2023-04-01
JP7094572B2 (ja) 2022-07-04
CN109748953B (zh) 2022-09-02
IL280565B (en) 2022-09-01
US20190169233A1 (en) 2019-06-06
JP6646017B2 (ja) 2020-02-14
KR102383710B1 (ko) 2022-04-08
KR20200037457A (ko) 2020-04-08
MX2019011621A (es) 2019-12-05
JP2020072717A (ja) 2020-05-14
US10487116B2 (en) 2019-11-26
CN110041403A (zh) 2019-07-23
CY1122453T1 (el) 2021-01-27
PH12021551208A1 (en) 2022-02-14
IL269753B (en) 2021-03-25
CN110041402A (zh) 2019-07-23
US10793602B2 (en) 2020-10-06
KR20220045085A (ko) 2022-04-12
US20200031867A1 (en) 2020-01-30
PH12018501901A1 (en) 2019-04-15
IL262509B (en) 2022-02-01
CL2018002494A1 (es) 2018-10-26
US11161880B2 (en) 2021-11-02
IL262509A (en) 2018-12-31
US20190177368A1 (en) 2019-06-13
CL2018002458A1 (es) 2018-10-12
US20190218254A1 (en) 2019-07-18
IL269753A (en) 2019-11-28
US11161877B2 (en) 2021-11-02
CL2018002493A1 (es) 2018-11-09
CN109748953A (zh) 2019-05-14
US20220281917A1 (en) 2022-09-08
US20220194984A1 (en) 2022-06-23
US11161878B2 (en) 2021-11-02
HUE057334T2 (hu) 2022-05-28
US20170320913A1 (en) 2017-11-09
IL280565A (en) 2021-03-25
IL295031A (en) 2022-09-01
CL2018002279A1 (es) 2018-09-14
HRP20192262T1 (hr) 2020-03-06

Similar Documents

Publication Publication Date Title
HK1222121A1 (zh) 用於治療多種腫瘤 例如包括 在內的肺癌 的新型免疫療法
IL280565A (en) New immunotherapy against various tumors such as lung cancer which includes nsclc
GB201507030D0 (en) Immunotherapy against lung cancers, in particular NSCLC
EP2971284A4 (en) Subtyping lung cancers
EP2968254A4 (en) Methods of treating lung cancer
GB201322725D0 (en) Cancer therapy
HK1220900A1 (zh) 癌症的治療
EP2994148B8 (en) Cancer therapy
EP3007756A4 (en) Catheter-assisted tumor treatment
EP3044593A4 (en) Cancer therapy
EP2961412A4 (en) CANCER THERAPY
EP3015476A4 (en) Tumor biomarker
EP3277325A4 (en) Combination immunotherapy for small cell lung cancer
IL245477B (en) Diagnosis of lung cancer
GB201313987D0 (en) Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GB201403297D0 (en) Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
GB201519261D0 (en) Novel Immunotherapeutic treatments for tumours
EP3077812A4 (en) Methods for the prognosis of breast cancer
GB201317213D0 (en) Cancer Therapy